We sought to determine if upstream amyloid accumulation and downstream cognitive impairment have independent relationships with microglial activation and tau pathology. Fifty-eight older adults were stratified by amyloid and cognitive status based on 18 F-florbetaben PET, history, and neuropsychological testing. Of these, 57 had 11 C-PBR28 PET to measure microglial activation and 43 had 18 F-MK-6240 PET to measure tau pathology. Amyloid and cognitive status were associated with increased overall binding for both 11 C-PBR28 and 18 F-MK-6240 (p's < 0.01). While there was no interaction between amyloid and cognitive status in their association with 11 C-PBR28 binding (p ¼ 0.6722), there was an interaction in their association with 18 F-MK-6240 binding (p ¼ 0.0115). Binding of both radioligands was greater in amyloid-positive controls than in amyloid-negative controls; however, this difference was seen in neocortical regions for 11 C-PBR28 and only in medial temporal cortex for 18 F-MK-6240. We conclude that, in the absence of cognitive symptoms, amyloid deposition has a greater association with microglial activation than with tau pathology.
Introduction
The emergence of b-amyloid pathophysiologyddefined by reduction of Ab 42 in CSF or by cortical retention of amyloid radioligands on PETdis the earliest detectable in vivo change in Alzheimer's disease (AD) pathogenesis . However, imaging studies have identified both cognitive controls with high amyloid signal and patients with Alzheimer's-like impairment with no apparent amyloid binding (Landau et al., 2016; Pike et al., 2011) , demonstrating that amyloidosis is neither necessary nor sufficient for clinical expression of an Alzheimer's phenotype. Therefore, other pathogenic factors appear to be required for cognitive decline, in both AD and in disorders that mimic AD.
Neuroinflammation is related to cognitive decline in AD. Binding of PET radioligands to the 18 kDa translocator protein (TSPO)da marker of microglial activationdis increased in AD and correlates with disease severity (Edison et al., 2008; Kreisl et al., 2013b Kreisl et al., , 2016 . However, neuroinflammation may be a nonspecific response to neurodegeneration, as TSPO binding is increased in several non-Alzheimer neurodegenerative disorders, including frontotemporal dementia, Parkinson's disease, and amyotrophic lateral sclerosis (Cagnin et al., 2004; Corcia et al., 2012; Gerhard et al., 2006) , and in vitro studies demonstrate microglial localization to axonal debris (Tanaka et al., 2009 ). On the other hand, recent genome-wide association studies identified mutations in microglia-expressed genes (e.g., TREM2 and CD33) that confer increased risk of AD (Colonna and Wang, 2016) . Moreover, results from tissue culture studies showed that physiological concentrations of Ab 42 stimulate microglia to release neurotoxic cytokines (Maezawa et al., 2011; Marlatt et al., 2014) , and inflammatory markers such as YKL-40 are elevated in CSF in the preclinical and prodromal stages of AD (Janelidze et al., 2018) . These latter results suggest that microglial activation appears early in AD pathogenesis, perhaps in response to early amyloid deposition, and may contribute to clinical progression.
PET imaging studies show that neurofibrillary aggregation of tau is more frequent in amyloid-positive than amyloid-negative controls (Jack et al., 2018; Schultz et al., 2018) , and tau pathology is generally detected after substantial amyloid plaque deposition . To date, only 2 PET studies have measured these 3 biomarkers in the same subjects. One study found correlations between TSPO and tau binding in both mild cognitive impairment and AD patients (Dani et al., 2018) ; however, correlations were also found in amyloid-negative subjects and the measured amount of TSPO binding was similar among patients and controls. The other study found no correlation between TSPO and tau binding (Parbo et al., 2018) . This latter study may have lacked sensitivity though, because of the low specific-to-nonspecific binding of the TSPO radioligand used, 11 C-(R)-PK11195.
We sought to determine how microglial activation and tau pathology relate to the upstream amyloidosis and downstream cognitive decline seen in AD. To achieve this goal, we stratified subjects by amyloid and cognitive status to test if amyloid-positivity and cognitive impairment are each independently associated with the amount of microglial activation and tau pathology measured with PET. We also sought to infer a temporal order of these Alzheimer's-associated markers from the cross-sectional imaging data. Microglial activation was measured using the TSPO radioligand 11 C-PBR28 (Briard et al., 2008; Lyoo et al., 2015) . Tau pathology was measured with 18 F-MK-6240, a recently developed radioligand that binds to paired helical filament tangles (Betthauser et al., 2019; Hostetler et al., 2016; Lohith et al., 2019; Pascoal et al., 2018) .
Materials and methods

Subject selection
Seventy-three adults aged 50 years and older were recruited from the Columbia University Irving Medical Center (CUIMC) Aging and Dementia clinic, self-referrals, the Columbia Alzheimer's Disease Research Center, and other research cohorts at CUIMC. All subjects underwent routine history, physical and neurological examination; routine laboratory studies; and a T1 MPRAGE (160 slice 1 mm resolution, 256 Â 200 voxel count) on a 3T Phillips Achieva MRI machine in the CUIMC Hatch MRI center.
These screening procedures were performed to rule out significant medical, neurological, or psychiatric illness; presence of cortical infarcts on imaging; and use of any immunosuppressive medication. All subjects (or their representative) provided informed consent according to the Declaration of Helsinki and this study was approved by the CUIMC Institutional Review Board.
Cognitive testing
Subjects who passed screening underwent neuropsychological testing, which included the Clinical Dementia Rating scale (Hughes et al., 1982) , MinieMental State Examination (MMSE) (Folstein et al., 1983) , Selective Reminding Test Delayed Recall (Ruff et al., 1989) , Trail Making Test Parts A and B, and Category and Phonemic Fluency. All cognitive test scores were transformed into z-scores using age-, sex-, and education-adjusted normative data. To be considered cognitively impaired, subjects had to have a primary memory complaint and meet clinical criteria for either amnestic mild cognitive impairment (MCI) (Albert et al., 2011 ) or AD (McKhann et al., 2011 . None of the impaired patients met clinical criteria for any specific disorder other than AD (e.g., dementia with Lewy bodies, vascular dementia, Parkinson's disease dementia, corticobasal degeneration, progressive supranuclear palsy, or frontotemporal dementia). Control subjects were free of any cognitive complaint, and history and neuropsychological test scores were used to confirm absence of clinically meaningful cognitive impairment.
TSPO genotyping
TSPO binding affinity was determined at screening. Genomic DNA from each subject was used to genotype the rs6971 polymorphism using a TaqMan assay (Owen et al., 2012) . Subjects homozygous for the low affinity allele were excluded from any further testing detailed in the following, and from the final analysis (n ¼ 8).
PET imaging
All PET imaging was performed in the CUIMC Kreitchman PET Center on the same Siemens Biograph mCT with low-dose CT scan used for attenuation correction. PET scans were performed on separate days. Amyloid status was determined with 18 F-florbetaben (FBB) PET. FBB images were acquired from 50e70 minutes after injection (injected activity ¼ 300 MBq) in 4 Â 5 minutes frames. 11 C-PBR28 PET images were acquired 60e90 minutes after injection (injected activity ¼ 599 AE 140 MBq) in 6 Â 5 minutes frames. 18 F-MK-6240 images were acquired 80e100 minutes after injection (injected activity ¼ 172 AE 10 MBq) in 4 Â 5 minutes frames. All 11 C-PBR28 scans were performed within 12 months of MRI and FBB scan. Mean interval between 11 C-PBR28 and 18 F-MK-6240 scans was 6 AE 4 months for patients and 11 AE 7 months for controls. Subjects who had greater than 12 months delay between 11 C-PBR28 and 18 F-MK-6240 scans had neuropsychological testing and brain MRI repeated.
PET image processing
The FBB, 11 C-PBR28, and 18 F-MK-6240 PET images were processed using the same pipeline. Reconstructed PET images were first realigned and corrected for subject motion using SPM12 (Wellcome Centre for Human Neuroimaging.). Images were then preprocessed with PMOD 3.8 (PMOD Technologies) using the PNEURO tool. T1-weighted MRI scans were segmented and normalized to standard space and the Hammers-N30R83-1 MM atlas was used to define regions of interest (ROIs). The ROI volumes were then reverse-warped to the subject's native space. ROIs were inspected and manually corrected as necessary. PET images were coregistered to the native space MRI. For 11 C-PBR28 and 18 F-MK-6240, the coregistered PET images were then corrected for partial volume effects with the region-based voxelwise method (Thomas et al., 2011) . PET images from each acquisition (50e70 minutes for FBB, 60e90 minutes for 11 C-PBR28, 80e100 minutes for 18 F-MK-6240) were then averaged, and the native space ROIs were applied. Concentration of radioactivity (kBq/cc) was then extracted from each ROI.
Volume-weighted gray matter ROIs were created from the Hammers atlas ROIs, consisting of prefrontal cortex (middle frontal gyrus, inferior frontal gyrus, superior frontal gyrus, straight gyrus, anterior orbital gyrus, medial orbital gyrus, lateral orbital gyrus, posterior orbital gyrus); middle and inferior temporal gyri (medial part of anterior temporal lobe, lateral parts of anterior temporal lobe and middle and inferior temporal gyri); superior temporal gyrus (anterior part of superior temporal gyrus, posterior part of superior temporal gyrus); medial temporal cortex (amygdala, parahippocampal gyrus, and entorhinal cortex); posterior cingulate cortex; superior parietal lobule; inferior parietal lobule; striatum (caudate nucleus and putamen); and cerebellum. For FBB and 11 C-PBR28, the concentration of radioactivity of each ROI was then divided by that of the cerebellum to create standardized uptake value ratios (SUVRs), a method that has been validated for both tracers in prior studies (Bullich et al., 2017; Lyoo et al., 2015) . Because uptake of 18 F-MK-6240 is sometimes seen in the anterior lobe of the cerebellum (Betthauser et al., 2019) , likely due to spillover from ventral temporal cortex and occipital cortex or off-target binding in tentorium cerebelli, we used only inferior cerebellar gray matter as reference region for this radioligand. For 11 C-PBR28 and 18 F-MK-6240, SUVRs were calculated for both partial volumeecorrected and uncorrected images.
Amyloid status determination
Reconstructed FBB PET images were averaged to create a single image for each subject and a visual read by an experienced neurologist (WCK) blinded to the subject's diagnosis was used to determine the presence or absence of fibrillar amyloid plaque (Bullich et al., 2017) . ROI data from the 50e70 minutes FBB images were used to calculate a composite SUVR (weighted average of SUVRs from prefrontal cortex, middle, and inferior temporal gyri, superior temporal gyrus, medial temporal cortex, posterior cingulate cortex, superior parietal lobule, and inferior parietal lobule) using cerebellar gray matter as reference region.
T1 MRI analysis
Volumes for target ROIs (prefrontal cortex, middle, and inferior temporal gyrus, superior temporal gyrus, medial temporal cortex, posterior cingulate cortex, superior parietal lobule, inferior parietal lobule, striatum, and cerebellum) were derived using PMOD as detailed in 2.4.1. To determine if amyloid-negative patients had an Alzheimer's-like pattern of neurodegeneration, ROIs for the right and left hippocampi for all subjects were manually drawn by investigators blind to the diagnosis. The volume of each ROI was corrected for differences in brain size by dividing by the total intracranial volume.
Statistical analysis
Statistical analyses were carried out using SAS version 9.4 and R version 3.5.1. Subjects were classified based on their amyloid status and clinical profile (as described in 2.2 and 2.4.2) into one of 4 groups: (1) amyloid-positive patients, (2) amyloid-positive controls, (3) amyloid-negative patients, and (4) amyloid-negative controls. Mean and standard deviation was derived for key descriptive characteristics for each subgroup, and an analysis of variance was performed to assess between group differences in these descriptive statistics. To validate the visual read of amyloid status as described in 2.4.2, the composite FBB SUVR was compared between amyloid-positive and amyloid-negative subjects.
To determine if amyloid and cognitive status are related to microglial activation and pathological tau burden, we performed separate multivariate analyses of variance (MANOVA) for 11 C-PBR28 and 18 F-MK-6240 binding, using the 8 PMOD-derived target ROIs: prefrontal cortex; middle and inferior temporal gyri; superior temporal gyrus; medial temporal cortex; posterior cingulate; superior parietal lobule; inferior parietal lobule; and striatum. Amyloid and cognitive status were the independent variables. Age and TSPO genotype (for 11 C-PBR28 binding) were included in the model as covariates. We also tested for interactions between amyloid positivity and cognitive impairment. For all MANOVA analyses, the residuals were examined to check normality and sphericity.
To more closely determine if amyloid and cognitive status are related to microglial activation and tau burden on a regional level, we ran a univariate analysis of variance for each of the 8 target ROIs for both 11 C-PBR28 and 18 F-MK-6240 binding. Amyloid and cognitive status were the independent variables. Age and TSPO genotype (for 11 C-PBR28 binding) were included as covariates. We determined effect size using partial Eta-square and tested for interactions between amyloid and cognitive status. For this primary analysis, we applied Bonferroni correction to compensate for the 16 multiple comparisons (2 independent variables Â 8 regions).
In a secondary analysis, to determine when and where 11 C-PBR28 and 18 F-MK-6240 binding first increase, we stratified subjects along the AD clinical spectrum from normal aging to AD dementia (i.e., amyloid-negative controls, amyloid-positive controls, amyloid-positive patients with mild cognitive impairment, and amyloid-positive patients with dementia), and then performed a four-way ANOVA to test for between-group differences within each of the 8 aforementioned ROIs. Partial correlations, adjusting for age and TSPO genotype (for 11 C-PBR28), tested the relationships of MMSE score with 11 C-PBR28 and 18 F-MK-6240 binding in these ROIs as well. Partial correlations were also performed to test the relationship between 11 C-PBR28 and 18 F-MK-6240 binding in each region.
Results
Characteristics of included participants
Fifty-seven subjects completed screening procedures, MRI, and the 11 C-PBR28 scan: 23 amyloid-positive patients, 7 amyloid- Table 1 Descriptive data for subject participants based on amyloid and cognitive status a positive controls, 10 amyloid-negative patients, and 17 amyloidnegative controls. Forty-two of these (14 amyloid-positive patients, 7 amyloid-positive controls, 9 amyloid-negative patients, and 12 amyloid-negative controls), plus one amyloid-negative patient who did not undergo 11 C-PBR28 imaging, had 18 F-MK6240 PET. One amyloid-positive patient was unable to complete the SRT because of poor memory performance. Impaired status for this participant was assigned based on memory complaint corroborated by caregiver, 0/3 delayed recall on MMSE testing, and performance on nonmemory tests. Both patient groups had lower Selective Reminding Test Delayed Recall z-scores than the control groups (p's < 0.01); however, amyloid-positive patients had lower MMSE score than the other 3 groups (p's < 0.01). Both patient groups had smaller hippocampal volume (corrected for total intracranial volume) than the amyloid-negative controls (p's < 0.01). Amyloidpositive patients additionally had smaller corrected volume for inferior parietal lobule than the other 3 groups (p's < 0.01), whereas amyloid-negative patients had smaller corrected volume for striatum than the other 3 groups (p's < 0.01). No group differences in corrected volume were seen for any other ROI. In agreement with our visual read of amyloid status, both amyloid-positive groups had greater FBB SUVRs in the composite ROI than the amyloid-negative groups (p's < 0.01). Table 1 shows demographic and clinical information for the 58 participants included in the analysis. The number of high affinity ("HAB") and mixed affinity ("MAB") binders in each group are also reported.
3.2. Effect of amyloid status and cognitive impairment on 11 C-PBR28 binding
We first tested how microglial activation relates to amyloid and cognitive status. We found that amyloid positivity, cognitive impairment, greater age, and high affinity TSPO genotype all had positive associations with overall 11 C-PBR28 binding (p's < 0.01). However, we found no interaction between amyloid status and cognitive status (p ¼ 0.6722).
We then looked at regional effects of amyloid and cognitive status on microglial activation. After correcting for age and TSPO genotype, we found a positive association of both amyloid positivity and cognitive impairment on 11 C-PBR28 binding in most target ROIs (Table 2) . Amyloid positivity was associated with greater 11 C-PBR28 binding in all regions except for the striatum. Cognitive impairment was associated with greater 11 C-PBR28 binding in all regions except superior temporal gyrus and striatum. There were no interactions between amyloid status and cognitive status observed in any region. The independence of amyloid-positivity and cognitive impairment resulted in additive effects on 11 C-PBR28 binding, such that amyloid-positive patients had greater binding than amyloidnegative controls, with amyloid-positive controls and amyloidnegative patients having intermediate binding ( Fig 1A) .
Increased age was associated with greater 11 C-PBR28 binding in middle and inferior temporal gyri, superior temporal gyrus, and medial temporal cortex (p's < 0.05). TSPO genotype had an effect on 11 C-PBR28 binding in middle and inferior temporal gyri, medial temporal cortex, posterior cingulate cortex, superior parietal lobule, and striatum (p's < 0.05).
The results of the analyses using 11 C-PBR28 data uncorrected for partial volume effects generally agreed with those using partial volumeecorrected data. Uncorrected SUVRs for each group are reported in Supplementary Table 1 .
Effect of amyloid status and cognitive impairment on 18 F-MK-6240 binding
When we tested how tau pathology relates to amyloid and cognitive status, we found that amyloid positivity (p ¼ 0.0007) and cognitive impairment (p ¼ 0.0025) were associated with greater 18 F-MK-6240 binding. However, unlike with 11 C-PBR28 binding, we found an overall interaction between amyloid positivity and cognitive impairment (p ¼ 0.0115). The interaction between amyloid positivity and cognitive impairment resulted in a multiplicative effect on 18 F-MK6240 binding, such that binding was increased in amyloid-positive patients and low in the other 3 groups (Fig 1B) . There was no effect of age on 18 F-MK-6240 binding (p ¼ 0.2987).
When we looked at regional effects of amyloid and cognitive status on tau pathology, we found that both amyloid positivity and cognitive impairment were associated with greater 18 F-MK-6240 binding in all measured ROIs (p's < 0.05, Table 3 ). Positive interactions between amyloid positivity and cognitive impairment were observed in all ROIs (p's < 0.05) except prefrontal cortex (although an interaction was seen here at trend level with p ¼ 0.0757) and striatum (p ¼ 0.5546). We found no effect of age in any ROI. As with 11 C-PBR28, the results of the analyses using data uncorrected for partial volume effects generally agreed with those using partial volumeecorrected data. Uncorrected SUVRs for each group are reported in Supplementary Table 2 .
We corrected for MANOVAs performed (testing microglial activation and tau pathology). After multiple comparisons corrections, all significant comparisons survived.
Microglial activation and tau pathology along the Alzheimer's clinical spectrum
We next stratified subjects who had 11 C-PBR28 PET along the Alzheimer's clinical spectrum, including amyloid-negative controls (normal aging, n ¼ 17), amyloid-positive controls (early Alzheimer's pathophysiological change, n ¼ 7), amyloid-positive patients with MCI (the clinical prodrome of AD, n ¼ 7), and amyloid-positive patients with AD dementia (full clinical expression of the disease, n ¼ 16). We found that 11 C-PBR28 binding increased in a stepwise manner, particularly in neocortical ROIs (Fig 2A, Table 4 ). Thus, each disease stage showed greater 11 C-PBR28 binding than an earlier disease stage, with temporal and parietal ROIs showing the largest differences.
We then stratified subjects who had 18 F-MK-6240 PET along the Alzheimer's clinical spectrum, including amyloid-negative controls (n ¼ 12), amyloid-positive controls (n ¼ 7), amyloid-positive patients with MCI (n ¼ 4), and amyloid-positive patients with AD dementia (n ¼ 10). We found that 18 F-MK-6240 binding increased along the AD spectrum; however, the pattern was different from that seen with 11 C-PBR28 ( Fig 2B, Table 5 ). The earliest Alzheimer's pathophysiological change was associated with increase in 18 F-MK-6240 binding in medial temporal cortex only, with increase in neocortical binding seen only in the MCI and AD groups.
Correlations between 11 C-PBR28 binding and MMSE score showed that 11 C-PBR28 binding was negatively associated with MMSE score in all ROIs except striatum (p's < 0.01) when all participants were combined. When we stratified participants based on Fig. 2 . 11 C-PBR28 and 18 F-MK-6240 binding stratified across the Alzheimer's disease continuum. (A) For 11 C-PBR28, binding increases in a stepwise pattern across the continuum in superior parietal lobule, such that increased binding is seen even in amyloid-positive controls. However, in medial temporal cortex, increased binding is seen only in amyloidpositive MCI and AD patients. (B) The opposite pattern is seen for 18 F-MK-6240, where increased binding is only seen in amyloid-positive MCI and AD patients in superior parietal lobule. However, in medial temporal cortex, a stepwise pattern is seen, with increased binding in amyloid-positive controls. Abbreviations: AD, Alzheimer's disease; MCI, mild cognitive impairment; SUVR, standardized uptake value ratio. amyloid status, this negative correlation remained for amyloidpositive subjects in each ROI except medial temporal cortex (p's < 0.05) (Fig 3A, Supplementary Fig 1) . 11 C-PBR28 binding did not correlate with MMSE score when only amyloid-negative participants were included. Similar to 11 C-PBR28, when all subjects who had 18 F-MK-6240 PET were included (n ¼ 43), binding negatively correlated with MMSE score in all ROIs, including striatum (p's < 0.01). Negative correlations were seen among amyloid-positive subjects in all ROIs (p's < 0.05) and no correlations were seen in amyloid-negative subjects when considered separately (Fig 3B, Supplementary Fig  2) . Correlation analyses using 11 C-PBR28 and 18 F-MK-6240 data uncorrected for partial volume effects followed a similar pattern ( Supplementary Fig 3 and 4) .
Correlation between microglial activation and tau deposition
For subjects with both 18 F-MK-6240 PET and 11 C-PBR28 PET performed (n ¼ 42), we performed a correlation between these radioligands to look for regional relationships between TSPO and tau. Using the partial volumeecorrected SUVR data, we found a significant positive correlation between 18 F-MK-6240 and 11 C-PBR28 binding in every region except the striatum (p's < 0.005). Results from correlation analysis using imaging data uncorrected for partial volume effects followed a similar pattern ( Supplementary  Table 3 ).
Discussion
We demonstrated that amyloid positivity and cognitive impairment are independently associated with 11 C-PBR28 binding. These results suggest that increased microglial activation co-occurs with amyloid plaque deposition in the absence of cognitive impairment and with cognitive impairment in the absence of amyloidosis. Because cognitive impairment is the clinical result of neurodegeneration, our results argue that microglial activation could be both a specific response to amyloid plaque deposition in early stages of AD and a nonspecific response to neurodegeneration in both Alzheimer's and non-Alzheimer's dementias. By contrast, amyloid and impairment interact in their association with 18 F-MK-6240 binding, such that binding is synergistically increased in amyloid-positive patients but not increased in amyloid-negative patients. These results suggest that tau pathology is most often seen when both amyloid and cognitive impairment are both already present. That 11 C-PBR28 and 18 F-MK-6240 binding negatively correlate with MMSE score among amyloid-positive subjects suggests a unidirectional increase in both microglial activation and tau pathology throughout the progression of AD.
We also found that 11 C-PBR28 and 18 F-MK-6240 showed different patterns of binding along the AD clinical spectrum. 11 C-PBR28 binding increased in a stepwise pattern in temporoparietal neocortex, starting in amyloid-positive controls. By contrast, 18 F-MK-6240 binding was increased in amyloid-positive controls only in medial temporal cortex, with neocortical increases only seen in MCI and AD patients. These results seem to agree with earlier observations with 18 F-AV-1451 that showed amyloid-positive controls were more likely than amyloid-negative controls to have high tau PET signal, particularly in medial temporal regions (Lowe et al., 2017) . Notably, in our study, we found an interaction between amyloid positivity and cognitive impairment on 18 F-MK-6240 binding in the medial temporal cortex (p < 0.01), suggesting that even in this region increased tau pathology is related to antecedent amyloid deposition. These results suggest a possible temporal order of Alzheimer's pathophysiology beginning with deposition of amyloid plaque, subsequent microglial activation in the neocortex, and increased tau pathology in the medial temporal cortex. These events are then followed by the appearance of increased tau pathology in neocortex and concurrent onset of memory impairment. Alternatively, it is possible that neuroinflammation and tau deposition occur at the same time, as 18 F-MK6240 may be less sensitive than 11 C-PBR28 in detecting small changes in pathology. In either case, these cross-sectional findings require confirmation in a longitudinal study as conclusions about temporal order cannot be made in a cross-sectional study.
That amyloid positivity and memory impairment are independently associated with increased 11 C-PBR28 binding is consistent with distinct roles of microglial activation at different time points: an early response to amyloidosis and a later response to neurodegeneration, the latter not necessarily specific to Alzheimer's pathogenesis (Sierra et al., 2013) . Increased TSPO binding in amyloid-positive controls has been previously reported (Hamelin et al., 2016) . Downstream response of microglia to neurodegeneration has been demonstrated by their activation in the presence of axonal injury (Tanaka et al., 2009) , and would explain increased TSPO binding in a variety of neurodegenerative diseases (Schain and Kreisl, 2017) . However, imaging studies alone cannot determine Fig. 3 . Both 11 C-PBR28 and 18 F-MK-62420 binding negatively correlate with MinieMental State Examination score. Scatter plots for inferior parietal lobule with best-fit lines are shown for 11 C-PBR28 (A) and 18 F-MK-6240 (B). Significant correlations are seen in amyloid-positive (red) but not amyloid-negative subjects (blue) for both radioligands. Closed circles ¼ impaired patients, open circles ¼ cognitively normal controls. Partial Pearson correlation coefficients (corrected for age and in the case of 11 C-PBR28 TSPO genotype) and pvalues are shown. Scatter plots for other ROIs are included in Supplementary Fig. 1 . Abbreviations: ROI, region of interest; SUVR, standardized uptake value ratio. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) the functional role of microglia in AD. Whether microglial activation plays a protective or pathogenic role in the preclinical stage remains unclear, as both phagocytic behavior and release of neurotoxic cytokines have been observed by microglia in response to b-amyloid species in vitro (D'Andrea et al., 2004; Maezawa et al., 2011) . Although some investigators have posited a bimodal relationship between TSPO and AD progression (Calsolaro and Edison, 2016; Fan et al., 2017; Hamelin et al., 2016) , the independent associations of 11 C-PBR28 binding with amyloid positivity and cognitive impairment, and apparent linear increase in 11 C-PBR28 binding along the disease spectrum, suggest a unimodal increase in overall microglial activation throughout the Alzheimer's process.
The underlying pathologies of the included amyloid-negative subjects with cognitive impairment are not known, but no participant had cardinal symptoms of dementia with Lewy bodes, frontotemporal dementia, progressive supranuclear palsy, corticobasal syndrome, or vascular dementia. Our amyloid-negative patients, on average, had smaller hippocampal volumes than our amyloidnegative controls, suggesting these patients in general had an Alzheimer's-like pattern of neurodegeneration. Hippocampal sclerosis and argyrophilic grain disease are 2 AD mimics potentially represented among patients lacking Alzheimer's pathophysiology (Jicha et al., 2006) . Because cognitive impairment was associated with increased 11 C-PBR28 binding in the absence of amyloid pathophysiology, TSPO PET could potentially be used as a disease marker in non-Alzheimer amnestic disorders for which no in vivo molecular biomarkers yet exist.
To our knowledge, this is the first study to use 11 C-PBR28 to measure microglial activation and 18 F-MK-6240 to measure tau pathology in the same participants. Prior studies used 11 C-(R)-PK 11195 to measure TSPO binding (Parbo et al., 2018) and/or 18 F-AV-1451 to measure tau binding (Dani et al., 2018) . 11 C-PBR28 has greater specific-to-nonspecific binding than 11 C-(R)-PK 11195 Kreisl et al., 2010) ; has been validated in AD subjects using a 30 minutes imaging window (Lyoo et al., 2015) ; has demonstrated longitudinal increases in AD (Kreisl et al., 2016) ; and co-localizes to neurodegeneration in vivo (Kreisl et al., 2017b) and microglial activation ex vivo (Kreisl et al., 2017a) . Based on our prior study (Lyoo et al., 2015) , SUVR measurement of 11 C-PBR28 binding results in greater statistical power than kinetic modeling using the arterial input function in detecting differences between AD patients and controls. Therefore, the SUVR approach with 11 C-PBR28 may be preferred over full quantification for detecting small differences in 11 C-PBR28 binding, such as that seen between amyloid-negative and amyloid-positive control groups. We recently demonstrated that using supervised clustering analysis also resulted in improved ability to detect increased 11 C-PBR28 binding in patients with AD compared with kinetic modeling with the arterial input function (Fregonara et al., 2019) . Although using SUVR has not been directly compared with using supervised clustering analysis, either approach appears to be a suitable alternative to arterial sampling, at least in cross-sectional studies. The SUVR approach has the additional advantage of shorter imaging times (and therefore reduced participant burden). 18 F-MK-6240 appears to have less off-target binding in choroid plexus and basal ganglia than 18 F-AV-1451 (Betthauser et al., 2019) . Moreover, the 2 studies using 18 F-AV-1451 showed somewhat discordant results, with one showing a correlation between these 2 radioligands (Dani et al., 2018) and the other finding no correlation (Parbo et al., 2018) . Interestingly, our results are more in line with that of Dani et al., which similarly used 11 C-PBR28 for TSPO imaging. Using 11 C-PBR28 and 18 F-MK-6240 together may have increased the sensitivity of detecting increased TSPO and tau pathology in our study. Correction for partial volume effects is an important consideration in AD studiesdas atrophy of the cerebral cortex exacerbates the partial volume effects from CSF inherent in PET imagingdand may be a more accurate representation of true radioligand activity (Su et al., 2015) . Although corrected data resulted in larger effect sizes, the direction of the relationships between radioligand binding and the comparative outcome variable remained the same regardless of whether partial volume correction was applied (see Supplementary Information) . In addition, that we still found correlations between 11 C-PBR28 and 18 F-MK-6240 and MMSE score in amyloid-positive subjects in partial volumeeuncorrected image data argues that our results were not simply due to over-estimation caused by partial volume correction.
Our conclusions are somewhat limited by our sample size. Although we obtained PET imaging in 58 participants overall, only 10 amyloid-negative patients and 7 amyloid-positive controls had 11 C-PBR28 PET imaging. In addition, the smaller number of participants in these 2 groups reflects the lower likelihood of amyloidnegativity in amnestic patients with AD patterns of neurodegeneration and of amyloid-positivity in controls, particularly given the relatively young ages included (69.2 AE 4.3 years for controls overall). While enrolling older participants is expected to increase the prevalence of amyloid-positivity in controls (Chetelat et al., 2013) , this approach would also increase the prevalence of non-Alzheimer co-pathology in the amyloid-positive patient group. The young age of amyloid-positive patient group (65.8 AE 8.4 years) reduces the likelihood that concomitant neurodegenerative disorders influenced our results. That 11 C-PBR28 binding is influenced by TSPO genotype introduces an element of variability in the analysis, and is a shortcoming of this radioligand. However, excluding low affinity binders and including TSPO genotype in the statistical analysis, as performed in this study, has been shown to overcome the confounding effects of this nuisance variable (Kreisl et al., 2013a, b) . Another limitation of our study is that only a subset of participants underwent 18 F-MK-6240 PET. However, the large dynamic range of this radioligand and large effects sizes seen in ours and prior studies (Betthauser et al., 2019; Lohith et al., 2019; Pascoal et al., 2018) argue that even modestly sized studies have sufficient power to see group differences in 18 F-MK-6240 binding.
In conclusion, amyloid positivity and memory impairment are independently related to 11 C-PBR28 binding. By contrast, amyloid and impairment interact in their relationship with 18 F-MK-6240 binding.
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